All lobbying filings

Forbes-Tate

Forbes-Tate filed a Q3 report for Genentech on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for Genentech · A biotechnology corporation

As filed: FORBES-TATE for GENENTECH.

All filings by Forbes-Tate · Everything Genentech has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Issues related to intellectual property and process patent.

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.

Taxation/Internal Revenue Code

Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Manufacturing

Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Budget/Appropriations

Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Health Issues

Issues related to the 340B Drug Pricing Program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.